Fuzeon Injection and Kaletra

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with ritonavir and/or saquinavir may slightly increase the plasma concentrations of enfuvirtide. The mechanism of interaction is unknown. According to the manufacturer, ritonavir (200 mg every 12 hours for 4 days) increased the steady-state peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough concentration (Cmin) of enfuvirtide (90 mg twice a day) by 24%, 22% and 14%, respectively, in 12 HIV-positive subjects. Saquinavir-ritonavir (1000 mg-100 mg every 12 hours for 4 days) increased enfuvirtide AUC by 14% and Cmin by 26% but did not affect Cmax. These alterations are not considered to be clinically significant.

Fuzeon Injection

Generic Name: enfuvirtide

Brand name: Fuzeon

Synonyms: Fuzeon

What is Fuzeon Injection?

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?